| Previous Close | 0.3680 |
| Open | 0.4000 |
| Bid | 0.0000 x 1000 |
| Ask | 0.5000 x 800 |
| Day's Range | 0.3502 - 0.4000 |
| 52 Week Range | 0.3500 - 3.7100 |
| Volume | 654,316 |
| Avg. Volume | 873,220 |
| Market Cap | 17.898M |
| Beta (3Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3080 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.14 |
Q1 2019 Viveve Medical Inc Earnings Call
ENGLEWOOD, CO / ACCESSWIRE / June 11, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Raymond James Life Sciences and MedTech Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.
By Brian Marckx, CFA READ THE FULL VIVE RESEARCH REPORT NASDAQ:VIVE Viveve (NASDAQ:VIVE) reported financial results for their fiscal Q1’19 and provided a business update. Relative to the financials, ...
- Successful organizational realignment resulting in decreased operating expenses - Significant progress in clinical programs targeting expanded indications in sexual function and stress urinary incontinence ...
ENGLEWOOD, CO / ACCESSWIRE / May 2, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2019 financial and operating results after the close of the U.S. financial markets on Thursday, May 9, 2019, and will host a live conference call and webcast at 5:00 PM ET the same day. A recording of the webcast will be posted on the company's investor relations website following the call at ir.viveve.com and will be available online for 90 days. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 11) Edap Tms SA (NASDAQ: EDAP ) Down In The Dumps (Biotech ...
ENGLEWOOD, CO / ACCESSWIRE / April 11, 2019 / Viveve Medical Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that the company received CE Mark clearance for its next generation Viveve 2.0 cryogen-cooled monopolar radiofrequency (CMRF) system and tips in the European Union. "As part of our ongoing regulatory strategy to expand the commercial launch of our Viveve 2.0 platform globally, we're extremely pleased that our next generation system and its consumable treatment tips are now available in over 30 countries in Europe.
Q4 Results: Warning Letter Headwinds Persist, Although Dissipating. Viveve (VIVE) reported Q4 financial results and provided a business update. While this is down 12% from the prior year, it is about 16% better than what we had anticipated (prior to the preannouncement) and, per management’s comments on the call, reflective of the continued hangover from FDA’s late-July warning letter (which, as a reminder, was not addressed to Viveve but did cause industry-wide disruptions).
Q4 2018 Viveve Medical Inc Earnings Call
Viveve Medical Inc is a women's sexual health company focused on the commercialization of a non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. Warning! GuruFocus has detected 4 Warning Signs with VIVE.
ENGLEWOOD, CO / ACCESSWIRE / March 14, 2019 / Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financial results for the three months ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 13) Abbott Laboratories (NYSE: ABT ) Akari Therapeutics ...
ENGLEWOOD, CO / ACCESSWIRE / March 11, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, announced today that it has completed enrollment in its VIVEVE II trial, a multicenter, randomized, double-blinded, sham-controlled study to evaluate the safety and efficacy of its proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of sexual function in women following vaginal childbirth. "Completion of enrollment in our VIVEVE II sexual function trial represents a tremendous milestone in our Company's quest to address an enormous unmet medical need for women. An estimated 12-14 million women worldwide suffer from diminished sexual function following vaginal childbirth.
ENGLEWOOD, CO / ACCESSWIRE / March 7, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it will report its fourth quarter and year-end 2018 financial results after the close of the U.S. financial markets on Thursday, March 14, 2019, and will host a live conference call and webcast at 5:00 PM ET the same day. A recording of the webcast will be posted on the company's investor relations website following the call at ir.viveve.com and will be available online for 90 days. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.
ENGLEWOOD, CO / ACCESSWIRE / March 5, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Cowen and Company 39th Annual Health Care Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference. The presentation will be webcast live on the Investors section of the Company's website at ir.viveve.com.
Earlier this week Viveve (VIVE) preannounced expected Q4 revenue of ~$4.4M (~16% ahead of our since-revised estimate), issued initial 2019 revenue guidance of $20.0M (~17% below our since-revised estimate) and outlined an already-underway operational restructuring plan aimed at slashing expenses and refocusing sales efforts at the physician (i.e. Q4 numbers (vs our estimates) are 57 (vs 55 E) unit sales, including 48 (vs 40 E) in the U.S. and 9 (vs 15) OUS and 4,600 (vs 5,047 E) consumable treatment tips. The ~$4.4M in expected Q4 revenue implies declines of 13% from Q4’17 and 8% from Q3’18.
Viveve Medical Inc. (VIVE), a medical technology company focused on women's intimate health, today reported preliminary financial results for the full year ended December 31, 2018 and provided revenue guidance for 2019. The company also announced it has implemented changes to the Viveve organization to reduce operating expenses and focus on label expansion and market development for its cryogen-cooled monopolar radiofrequency (CMRF) technology.
“As we seek to achieve regulatory clearances for our CMRF technology for the treatment of SUI, a condition that affects an estimated 25-30 million women worldwide, completion of enrollment in the LIBERATE-International trial is an important milestone,” stated Scott Durbin, chief executive officer and director of Viveve. “Our single-session procedure offers women the potential for significant improvement in urine leakage and the ability to engage in their daily lives with greater comfort and control. LIBERATE-International is a multicenter, randomized, double-blinded, and sham-controlled trial with an enrollment of approximately 100 subjects at up to ten study sites in Canada.
It has been a busy few weeks for Viveve (VIVE). In addition to raising nearly $19M (net) via the sale of common shares, they recently announced compelling 12-month results from their n=36 SUI feasibility study and got the green light from FDA to forge ahead with VIVEVE II (their pivotal U.S. study in sexual function). Earlier this month Viveve announced 12-month results of its feasibility study evaluating their Viveve System technology for the treatment of women with mild-to-moderate stress urinary incontinence (SUI).
Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to continue enrollment in the company’s multicenter randomized Viveve Treatment of the Vaginal Introitus to EValuate Safety and Efficacy (VIVEVE II) clinical trial to assess the safety and effectiveness of the Viveve® System for the improvement of sexual function in women following vaginal childbirth. The Agency determined that the company provided sufficient data to support continued subject enrollment in the trial and that there are no safety concerns that preclude the continuation of the study.
Viveve Medical, Inc. (“Viveve”) (VIVE), a medical technology company focused on women’s intimate health, today announced the closing of its previously announced underwritten public offering of 13,333,334 shares of its common stock at a public offering price of $1.50 per share. The net proceeds to Viveve from the offering were approximately $18.8 million, after deducting underwriting discounts and commissions (but before deducting estimated offering expenses payable by the Company). Viveve intends to use the net proceeds from this offering to support the continued commercialization of its products in North America and internationally, to obtain additional regulatory clearances and to conduct the VIVEVE II Sexual Function and LIBERATE – International and LIBERATE – U.S. stress urinary incontinence (SUI) clinical trials, and for general corporate and working capital purposes.
Viveve Medical, Inc. (“Viveve”) (VIVE), a medical technology company focused on women’s intimate health, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a public offering price of $1.50 per share. The gross proceeds to Viveve from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Viveve, are expected to be $20.0 million. All shares of common stock are being offered by Viveve.
Viveve Medical, Inc. (VIVE) (“Viveve”), a medical technology company focused on women's intimate health, today announced positive 12-month data from an investigator-initiated, single-arm, 12-month feasibility study using its cryogen-cooled, monopolar radiofrequency (CMRF) technology platform for the treatment of mild-to-moderate stress urinary incontinence (SUI) in women. The study was conducted by Bruce Allan, PhD, MD, FRCS(C), founder and medical director of the Allan Centre in Calgary, Alberta. “These positive results build upon the demonstrated effectiveness and durability of our single-session CMRF treatment for women experiencing SUI symptoms, as previously reported in the six-month interim data from this feasibility study, as well as the 12-month data in the separate SUI pilot study,” said Scott Durbin, chief executive officer and director of Viveve.
Viveve Medical, Inc. (“Viveve”) (VIVE), a medical technology company focused on women’s intimate health, today announced that it has commenced an underwritten public offering of shares of its common stock. All shares of common stock will be offered by Viveve. Viveve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock in connection with the public offering.
The live webcast of this event can be accessible through the company’s investor relations website at http://ir.viveve.com. Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. In the second quarter of 2018, Viveve initiated VIVEVE II, a multicenter, randomized, double-blind, sham-controlled study to assess improvement of sexual function in women following childbirth following an Investigational Device Exemption (IDE) application approval from the U.S. Food and Drug Administration (FDA) in March of 2018.